Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00151476 · ClinicalTrials.gov registry record
Observational Familial Adenomatous Polyposis Registry Study In Patients Receiving Celecoxib Compared to Control Patients
A clinical trial, sponsored by Pfizer.
- Terminated
- Registry status
- 68
- Enrollment target
NCT00151476 is a clinical trial that was terminated before completion, run by Pfizer. The registered enrollment target is 68 participants.
The verdict
NCT00151476 was terminated before completion, sponsored by Pfizer.
- TERMINATED
- Registry status
- 68 participants
- Enrollment target
Study Summary
This is a registry-based observational study assessing clinical outcomes in FAP patients receiving celecoxib compared with historical/concurrent registry patients who have not received celecoxib. Both retrospective and prospective data will be utilized. No sampling methods apply.
Interventions
- DRUG Celecoxib
- OTHER Routine Medical Care
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 68 participants |
| Start Date | 2004-11 |
| Est. Completion | 2008-11 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00151476
The ClinicalTrials.gov registry entry for NCT00151476 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 68 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Celecoxib is the first listed.
NCT00151476 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00151476 about?
NCT00151476 is a clinical study titled "Observational Familial Adenomatous Polyposis Registry Study In Patients Receiving Celecoxib Compared to Control Patients". This is a registry-based observational study assessing clinical outcomes in FAP patients receiving celecoxib compared with historical/concurrent registry patients who have not received celecoxib. Both retrospective and prospective data will be utilized. No sampling methods apply.
What is the current status of trial NCT00151476?
This trial is currently terminated. The enrollment target is 68 participants. The study started on 2004-11. Estimated completion is 2008-11.
What interventions are being tested in trial NCT00151476?
The interventions under investigation include: Celecoxib (DRUG), Routine Medical Care (OTHER).
Who is sponsoring clinical trial NCT00151476?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.